C92.00
Acute myeloblastic leukemia, not having achieved remission
Clinical Classification Guidelines
Inclusion Terms
- Acute myeloblastic leukemia with failed remission
- Acute myeloblastic leukemia NOS
Medical Intelligence & Overview
Acute myeloblastic leukemia (AML) is a fast-growing cancer of the blood and bone marrow that affects the production of white blood cells. When diagnosed as AML not having achieved remission, it indicates that the disease persists despite initial treatment attempts. This condition requires ongoing management and monitoring, as it is considered an aggressive form of leukemia.
Causes & Symptoms
Clinical Causes: Genetic mutations or changes in blood cell DNA Previous exposure to chemotherapy or radiation therapy Inheritance of certain genetic syndromes or conditions Environmental factors such as exposure to benzene or chemotherapy drugs History of other blood disorders or cancers
Key Symptoms: Unexplained fatigue or weakness Frequent or severe infections Fever or chills Easy bruising or bleeding Pale skin due to anemia Shortness of breath Bleeding gums or pinpoint red spots on the skin (petechiae) Bone or joint pain Night sweats Weight loss without trying
Diagnostic & Treatment
Diagnosis Path: Diagnosing AML involves a combination of medical history review, physical examination, and laboratory tests. Key steps often include: - Blood tests to detect abnormal white blood cell counts and other hematologic changes - Bone marrow aspiration and biopsy to examine abnormal cell populations - Cytogenetic and molecular studies to identify genetic mutations associated with AML Prompt diagnosis is crucial for determining the severity of the disease and planning appropriate treatment options.
Treatment Protocols: Treatment strategies for AML not having achieved remission typically involve aggressive and often multi-modal approaches: - Chemotherapy to destroy leukemia cells and attempt to induce remission - Targeted therapy aimed at specific genetic mutations - Supportive care, including blood transfusions and antibiotics to manage symptoms and infections - Stem cell or bone marrow transplant in suitable candidates to replace diseased marrow with healthy cells Due to its aggressive nature, ongoing monitoring and possibly multiple treatment cycles are common. The goal is to control the disease, improve quality of life, and extend survival.
Clinical Advice & FAQs
Billing Guidance
Is C92.00 a billable ICD-10 code?
Yes, C92.00 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C92.00?
Clinical documentation must specify the nature of Acute myeloblastic leukemia, not having achieved remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference